Director/PDMR Shareholding

RNS Number : 0310Q

GlaxoSmithKline PLC

27 July 2010

 



This announcement replaces the original announcement released on 1 July 2010 at 15.58 (RNS No: 6764O).

The Company was notified on the 27 July 2010 of a correction to the number of shares provisionally allocated to the Company's Non-Executive Directors' Mr Lawrence Culp and Sir Deryck Maughan pursuant to the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2010 to 30 June 2010.

Save as disclosed above and the revised details shown below, all other details remain unchanged.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.

On 30 June 2010, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £11.37 per Ordinary share and $34.05 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2010 to 30 June 2010:

Non Executive Director	Ordinary Shares	American Depository Shares (ADSs)
Sir Christopher Gent	2,968.34
Prof. Sir Roy Anderson	577.18
Dr Stephanie Burns		809.11
Mr Lawrence Culp		1,258.61
Sir Crispin Davis	2,088.83
Sir Deryck Maughan		1,258.61
Mr James Murdoch	1,649.08
Dr Daniel Podolsky		1,483.36
Mr Tom de Swaan	852.02
Sir Robert Wilson	577.18

The Company and the Non-Executive Directors were informed of these allocations on 1 July 2010.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell

Company Secretary

1 July 2010

 

END

 

 

RDSDDLFLBDFLBBV